Millennium To Begin Phase III Trial For Velcade As First-Line Treatment For Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Velcade and Celgene’s Revlimid competing to be first with a first-line indication in MM.
You may also be interested in...
sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.
sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.
Revlimid Data Could Support First-Line Use In Multiple Myeloma
Higher survival rate is seen with Revlimid in combination with lower-dose dexamethasone compared to use with a higher dose of the steroid.